New Pd(II) and Pt(II) complexes are described in which the multidentate phosphorus ylides [Ph 2 P(CH 2 ) n PPh 2 = C(H)C(O) C 6 H 4 -p-OCH 3 ] (n = 1, (Y1); n = 2, (Y2)) act as P,C chelating ligands. The chelating ability of these ligands resulted in the formation of [MBr 2 {K 2 (P,C)-Y1}] (M = Pd (1), Pt (2)); [MBr 2 {K 2 (P,C)-Y2}] (M = Pd (3), Pt (4) complexes, which were investigated using physicochemical techniques. X-ray diffraction studies of a single crystal of complex 2 confirmed the structure of the fivemembered ring. Owing to the redox activity of phosphorusylide complexes, their electrocatalytic activity for the oxidation of methanol has been studied. All compounds were found to possess the anti-proliferative potency against MCF-7 (breast carcinoma), A549 (non-small lung carcinoma) and AGS (gastric carcinoma) cell lines with average IC 50 values in the range of 14.53 to 287.92 μM. In general, the compounds Y1, Y2, 2, and 3 displayed high anticancer activities compared to 1 and 4. The antioxidant activity of the compounds, which was estimated by 1, 1-diphenyl-2-picryl-hydrazyl (DPPH) free radical scavenging, was moderate to strong with IC 50 values in the range 0.18 to 0.59 mg mL À 1 .
Introduction
Phosphorus ylides can be viewed as dipolar molecules, in which a carbanion is directly connected to a phosphorus atom with a high degree of formal positive charge. This bonding feature renders phosphorus ylides into attractive reagents for organic synthesis. [1À 3] Phosphorus-ylide complexes, due to their different oxidation states, can be used as catalyst in various reactions, for example, the hydrogenation of olefins, [4] polymerization of acetylenes [5] and the Suzuki reaction of various aryl halides. [6, 7] Due to the effect of the catalyst in electro-reduction and electro-oxidation reaction efficiency, the role of the catalyst can be considered key for the electro-oxidation of methanol in fuel cells. [8, 9] Many materials such as carbon nanotubes (CNTs), [10] Schiff base complexes. [11, 12] Ni-based nanoparticles (NPs) [11] have shown to be effective in catalyzing electrochemical reactions. Also, Pd/Pt-based complexes can be used for catalyzing electrochemical reactions in fuel cells, resulting in a decrease in over-potentials and an increase in peak currents.
Many cellular functions are affected by free radicals including various reactive oxygen species (ROS), which are involved as essential modulators in the cell signaling pathways associated with differentiation, proliferation, and apoptosis. Despite the fact that low levels of intracellular ROS are essential for the cellular functions, their high amounts eventually result in oxidative stress. Oxidative stress is one of the main reasons of lipid peroxidation and oxidative damage to DNA and RNA molecules and proteins. Consequently, oxidative stress plays a key role in the development of sicknesses such as chronic diseases, cancer and other disorders. [13À 15] Human society is facing multiple challenges regarding health. In particular, cancer still is a horrible disease that kills many people every year around the world. [16] Medicinal inorganic chemistry can help to diagnose and battle of several cancers. [17] In recent years, researchers have attempted to identify, design and synthesize the novel antioxidant compounds which are potent, selective, less toxic and effective in treating several diseases particularly cancer. [14, 15, 18] Since about 40 years ago, cisplatin [cis-diamminedichloridoplatinum(II)] and its derivatives, because of its ability to interact with DNA, are routinely prescribed as chemotherapeutic agents to treat testicular and ovarian cancers, and is extensively used against a variety of other tumors, comprising cervical, bladder and those of the head and neck. [17,19À 22] Previous studies illustrated that trans platinum(II) and palladium(II) complexes had anticancer potency against ovarian, colon, renal, and melanoma cancer cell lines. [23, 24] Nevertheless, use of these complexes as antitumor agents has some problems such as accumulative toxicities of nephrotoxicity and ototoxicity. Additionally, the final success of these compounds is also hindered by clinical problems such as intrinsic or acquired drug-resistant tumor cells and a limited spectrum of activity. [25] As well, they show several side effects such as nausea and myelosuppression. [20] Hence, these disadvantages have triggered a profound interest in designing and screening of substitute chemotherapeutic drugs. Accordingly, a novel class of metal compounds should have different chemical behavior, rates of hydrolysis and action mechanism in order to reveal a wider range of anti-proliferative activity and low side-effects.
To the best of the author's knowledge, palladium and platinum complexes, show biological activities, especially antitumor effects. In comparison, platinum and palladium have a noteworthy similarity in terms of the coordination chemistry. [18] Based on our literature review, palladium (II) complexes generally disclose a lower antitumor potential than cisplatin because they have a more labile nature in comparison to the corresponding platinum (II) complexes. [18, 26] Though, in 2004, some palladium (II) complexes synthesized by Budzisz et al. had a higher anti-cancer effect than cisplatin and carboplatin. [27] In the current paper, we selected the ylides [Ph 2 P(CH 2 ) n PPh 2 = C(H)C(O)C 6 H 4 -p-OCH 3 ] (n = 1, (Y1); n = 2, (Y2)) to participate as ligands for the preparation of new Pd(II) and Pt(II) complexes. Also, we reported in vitro testing of the preliminary anti-proliferative activities on the human MCF-7 breast, A-549 lung and AGS gastric cancer cell lines. Moreover, we report the antioxidant capacity of the synthesized compounds. As part of this study, we have used the synthesized complexes as catalyst in the oxidation of methanol, because methanol has been considered to be a source of green power with relatively high activity in fuel cell systems. [28, 29] 
Results and Discussion

Synthesis
The addition of [MBr 2 (COD)] (where M = Pd or Pt) to phosphorus ylides Y1 and Y2 in a 1:1 M ratio resulted in the formation of the new cyclometalated complexes (1-4) (see Scheme 1).
Spectroscopy
1 H, 13 C{ 1 H} and 31 P{ 1 H} NMR and other conventional techniques such as IR and elemental analysis have attested the structure of the products. Also, for obtaining the exact structure of the complexes, the structure of 2 was assessed via single crystal Xray diffraction analysis.
The characteristic of compounds in IR spectroscopy is a carbonyl functional group. As noted in the literature, [30] coordination of the phosphorus ylides through carbon (chelating mode) causes a significant increase in the ν(CO) frequency. In the IR spectra of phosphorus ylides Y1 and Y2, the ν(CO) was observed at lower frequencies than those of the related phosphonium salts. Complexes 1-4 showed a ν(CO) band in the range of 1617-1628 cm À 1 , which is shifted to higher frequencies compared to corresponding ylides [ Table 1 ]. The presence of the ν(CO) bands at around 1600 cm À 1 indicated the products (i. e., P,C-chelated complexes) were formed. Due to disappearing of the ν(CO) bands at around 1500 cm À 1 , P,Pcoordinated complexes have not been formed. In the 31 P { 1 H} NMR spectra, the coordination of phosphorus ylides in the P,C-chelated form created a large chemical shift for both (PPh 2 ) and (PCH) phosphorus groups. The 31 P { 1 H} NMR spectrum of palladacycles 1 shows two doublet peaks in area δ = 28.33 and 39.1 ppm, which is assigned to PPh 2 (P a ) and PCH (P b ), respectively ( Figure 1 ). The 31 P{ 1 H} NMR spectrum of platinacycle 2 displays two doublet peaks at around δ = 6.47 along with two satellite peaks due to 195 Pt-31 P coupling and 43.56 ppm, which is assigned to PPh 2 (P a ) and PCH (P b ), respectively ( Figure 1 ). [7, 31] The 31 P { 1 H} NMR spectrum of palladacycles 3 shows two doublet peaks in area δ = 22.93 and 30.68 ppm, which is assigned to PPh 2 (P a ) and PCH (P b ), respectively. The 31 P NMR spectrum of platinacycle 4 shows two doublet peaks at around δ = 6.2 and 19.73 ppm (along with two satellite peaks due to 195 Pt-31 P coupling), which is assigned to PPh 2 (P a ) and PCH (P b ), respectively (see Supporting Information).
CH signals in the 1 H NMR spectra display characteristic shifts in the Pd(II) and Pt(II) complexes with respect to the parent phosphorus ylide. Methinic protons in the ylides Y1 and Y2 appear around 4 ppm. [32] The same signals in the Pd(II) and Pt (II) complexes 1-4 emerge around 6 ppm. This downfield shift indicates that complexation of the ylides to metals has occurred through P and Cα atoms [see Supporting Information].
The 13 C NMR spectra of the carbonyl group in phosphorus ylides Y1 and Y2 are around 185 ppm, whereas the same carbon in the complexes 1-4 is around 195 ppm. These observations show a much lower shielding of the CO group in these complexes compared to phosphorus ylides. As a result, the spectral data show that chelating is done through the phosphine group and the ylidic carbon atom [see Supporting Information]. A brief summary of the data sets is presented in Table 1 .
Crystallography
Suitable crystals of complex 2 were grown by slow evaporation of their dichloromethane solution. The molecular structure of 2 is shown in Figure 2 . Relevant parameters concerning data collection and refinement are given in Table 2 , while selected bond distances and angles are displayed in Table 3 . The asymmetric unit of the structure of 2 contains two [PtBr 2 {K 2 (P,C)-Y1}] complexes. The two complexes only differ slightly in the orientation of the phenyl rings of the phosphorus ylide and C 6 H 4 -p-OCH 3 parts. In both complexes, the Pt atom is four-coordinated by one P-atom of the phosphine group, one ylidic C-atom, and two bromine atoms, showing a slightly distorted square-planar geometry around the Pt metal, with τvalues of 0.06°and 0.04°(0.00°for perfect square planar), for Pt1 and Pt2, respectively. [33] For both complexes, the X-ray analysis unequivocally confirms the PÀ C chelating mode of the ligand Y1 to the Pt(II) metal center. The bond lengths of P(2)-C(26) and P(4)-C(66) are 1.800(13) Å and 1.783(13) Å, respectively, which is obviously longer compared to the bond length of PÀ C(H) in the parent ylides such as Ph 2 PCH 2 PPh 2 CH=C(O) [36, 37] 2.4. Biological evaluation
Cytotoxicity potency
The in vitro antitumor efficiency of the new compounds was investigated by means of a colorimetric micro-culture assay (MTT assay) against three selected human breast (MCF-7), lung (A549) and gastric (AGS) cell lines. Cytotoxicity of the Pd(II) and Pt(II) complexes 1-4, Y1 and Y2 ligands against MCF-7, A549 and AGS are expressed as a percentage of cell viability (S7, see Supporting Information). An IC 50 value is defined as the drug concentration required for killing 50% of the cells. IC 50 values of the studied complexes were calculated from the dose-survival curves for the growth inhibition of the three cell lines (Table 4 ).
In general, the cytotoxic potency of the compounds ranged extensively in the following order: Y2 > Y1 > 2 > 3 > 1 > 4. Additionally, based on the IC 50 values, the A549 cells (average IC 50 value; 78.81 μM) appear to be more chemo-sensitive to the compounds studied here than the MCF-7 and AGS cells ( Table 4 ). By assessing the cytotoxic potency of the complexes against human MCF-7 cells at 1.56, 3.13, 6.25, 12.50, 25 and 50 μM concentrations, Y2 showed a fairly cytotoxic potency with the half maximal inhibitory concentration (IC 50 ) of 5.68 � 1.95 μM (Table 4 ). Only 34% of breast cancer cells survived at 50 μM of Y2 (S7, see Supporting Information), which is considerably lower value than that reported for the related benchmark cisplatin drug with IC 50 of 15 � 2 μM, for these cancer cells. [38] Our findings also show that 2 and Y1 were effective against the MCF-7 cells with IC 50 levels of 52.88 and 66.24 μM, respectively. For compounds 3, 1 and 4, moderate cytotoxic activity was observed (S7, see Supporting Information). The effect of the synthesized compounds on the viability of the studied cancer cells indicates that the A549 cells are more susceptible to the compounds than the other two human adenocarcinoma cell lines (S7, see Supporting Information and Table 4 ). All of the complexes, apart from 1, when assessed against A549 human lung cancer cells, revealed moderate to excellent cytotoxic activity exhibiting IC 50 values as low as 35.97 μM. Y2, Y1 and 4 were the most active, displaying significantly low IC 50 values of 5.73, 11.97 and 12.32 μM, respectively. According to our results, both 3 (IC 50 ; 30.16 � 2.45 μM) and 2 (IC 50 ; 35.97 � 0.18 μM) compounds showed near-equal activities against A549 cells. In contrast, compound 1 required up to 376.69 μM to inhibit the growth of 50% of lung cancer cells.
The compounds Y1 and Y2 showed IC 50 values of 19.39 � 2.18 and 32.18 � 9.28 μM, respectively, when assessed against human gastric adenocarcinoma (AGS) cells, (Table 4 ). Although compound 1 (IC 50 ; 81.22 � 6.13 μM) was moderately cytotoxic, there was no significant difference between the antitumor activity of compounds 1 and 3. At lower doses, compounds 2 and 4 with 50% cytotoxic concentrations of 107.38 and 558.15 μM, respectively, were tolerated by the AGS cells. In agreement with Budzisz et al., [27] our results showed that the Pd (II) complexes had higher antiproliferative potency against the human gastric cell line than those of the Pt(II) complexes. Although all in vitro experiments hold limitations with respects to possible in vivo efficiency, the findings are very auspicious with regard to possible antineoplastic chemotherapy and form a very sound basis for future research. In the current study, the pattern of anticancer activity was investigated for the synthesized compounds to reassess the grouping boundaries. Based on the obtained PCoA plot from the IC 50 values of each compound against the cells, the compounds were distributed into three separate groups (Figure 3 ). The first group comprised the compounds Y2, Y1, 2, and 3, which display an average IC 50 values < 75 μM, interestingly; this group could be divided into two subgroups: (a) Y2 and Y1 were the most effective compounds in inhibiting growth of the studied cancer cells with the lowest average of IC 50 values of 14.5 and 32.5 μM, respectively, and (b) compounds 2 (average IC 50 value; 65.4 μM) and 3 (average IC 50 value; 74.4 μM), which showed moderate IC 50 values, it should be pointed out that both compounds 2 and 3 possess antitumor potential against the tested cell lines. The second and third groups included compound 1 (average IC 50 values; 191.3 μM) and 4 (average IC 50 values; 287.9 μM), respectively, which showed higher average IC 50 value against the cells. It was demonstrated that these compounds are not effective in growth inhibition of the studied cells.
Our findings showed that the synthesized compounds, especially Y2 and 4 had higher toxicity against A549 than other tested cancerous cells. A comparison between the cytotoxicity (IC 50 value based on μM) of the synthesized compounds in this study against these cells and other Pt/Pd-based complexes reported in literature was also undertaken and presented in (S8, see Supporting Information). [20] The results show that Y2 and 4, [PtBr 2 {K 2 (P,C)-Y 2 }], have similar and even higher antitumor potencies than the results recently reported for X5, [39] [PdCl(terpyridine)][saccharinate].2H 2 O. [20] [Pt(L-alanine-N'-8-quinolylamide)Cl] [40] and the Pd(II) 5,5-diethylbarbiturate complex The experiment was performed in triplicate and expressed as mean � SD. Values along each column with different superscripts are significantly different (P < 0.05).
with bis(2-pyridylmethyl)amine. [41] IC 50 values for all of these compounds against A549 were < 20 μM. Interestingly, the antiproliferative activities measured for Y2 and 4 are much higher than that reported for the other Pt/Pd-based complexes such as X3, [39] [Pd(bis(2-pyridylmethyl)amine)(saccharinate)] [saccharinate].H 2 O [20] and 4'-(4-hydroxyphenyl)-2,2',6',2''terpyridine. [20] In general, the results of studies on the effect of ligand and metal ions, especially Pt(II) and Pd(II), confirm that both of them have a significant effect on cancer cells and kill these cells.
Antioxidant activity
The antioxidant property of the compounds as assessed by DPPH free radical scavenging is summarized in Table 5 . The compounds exhibited a dose-dependent (0.2-1 mg mL À 1 ) antiradical activity (39.27-84.39% ). The scavenging activity is higher when the IC 50 value is low. The efficiency of the compounds as DPPH radical scavengers ranged in the following descending order: (a) Y2 (IC 50 ; 0.18 mg mL À 1 ), (b) Y1 (IC 50 ; 0.19 mg mL À 1 ), (c) 2 (IC 50 ; 0.19 mg mL-1), (d) 3 (IC 50 ; 0.20 mg mL À 1 ), (e) 1 (IC 50 ; 0.38 mg mL À 1 ), and (f) 4 (IC 50 ; 0.58 mg mL À 1 ). As shown in Table 5 , compound Y2 (54.94-84.39%) at high concentrations presented similar scavenging activity to ascorbic acid (72.54-81.37%) and quercetin (75.83-90.16%). The antioxidant potency of the compounds can be used as an appropriate tool to determine their classification and pharmaceutical importance. Results from the Cluster Analysis (CA) demonstrated that the studied compounds could be divided into two different groups based on their IC 50 values (Figure 4 ). The first group, as the largest group in the present work, contained two subgroups. The first one contained quercetin, ascorbic acid and Y2, which showed low IC 50 values (0.13-0.18 mg mL À 1 ), and the second subgroup consisted of Y1, 2, and 3, which represented the near IC 50 values to the first subgroup (0.19-0.20 mg mL À 1 ). It should be pointed out that these compounds had the high antiradical capacity. The second group consisted of the compound 1, which disclosed a moderate IC 50 value (0.38 mg mL À 1 ). This compound was built from Y1 and Pd(II). Similar to results from anticancer grouping, compound 4 showed a high IC 50 value, in comparison to the other appraised compounds. At the concentration of 1 mg mL À 1 , the antiradical ability and IC 50 value of 4 were 64.70% and 0.59 mg mL À 1 , respectively. Thus, compound 4 has the lowest antitumor and antioxidant activities. 
Electrocatalytic property
Referring to the proposed mechanism by Hosini et al, [11] the modified electrode (here Pd(II) and Pt(II) complexes) in alkaline medium oxidizes methanol. According to this, electrocatalytic activity of the synthesized complexes toward the oxidation of methanol was evaluated by cyclic voltammetry in an electrolyte of 0.5 M methanol and 0.5 M NaOH at a scan rate of 100 mV/s. The voltammograms of the modified electrodes with complexes are demonstrated in Figure 5 . The irreversible anodic peak in the range of 1.2 to 1.4 V in the voltammograms is related to the oxidation of methanol. The oxidation of methanol takes place through the reduction of Pd(IV) and Pt(IV) produced on the surface of electrode to Pd(II) and Pt(II). Based on these results, complexes 1-4 can exhibit electrocatalytic activity toward the oxidation of methanol. As can be noticed in Figures S17-S18 (see Supporting Information), regarding the structural similarity of the synthesized complexes, the oxidation peak of methanol at the modified electrode surface with the complexes has appeared at the same potential, and also the oxidation peak current was increased approximately in 0.95, 0.2, 1.3 and 0.89 mA for complexes 1-4, respectively. The oxidation peak current for complex 3 is greater than for the other complexes, indicating a small difference in the surface structure of the modified electrode with complex 3 in comparison with the other complexes.
Conclusions
The present study describes the synthesis and characterization of pallada-and platinacycle complexes incorporating unsym-metrical phosphorus ylides. The results reveal that the coordination of ligands to the Pd(II) and Pt(II) metals takes place through P, C atoms and makes five or six-membered chelate rings. The structure was confirmed by single crystal X-ray diffraction of complex 2. Also, study of the electrocatalytic activity shows that the complexes were found to be active catalysts in the electro-oxidation of methanol. Additionally, in vitro antitumor potency of the new complexes was appraised against a panel of cancer cell lines. The synthesized compounds display a high tumor-specific cytotoxicity against human lung adenocarcinoma cell line, demonstrating that they show potential as new drug candidates for cancer chemotherapy. Moreover, our results exhibit that the tested compounds possess considerable antioxidant ability. In conclusion, these compounds show outstanding biological properties and can be considered as an auspicious lead in cancer-treating drug discovery and development.
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